Developing Innovative Treatments for Various Forms of Life-Threatening Fibrotic Disease.
Therapeutic Focus
Neurodegenerative Disease
Molecular Imaging & Radiotherapy
Fibrotic Disease
Diagnostics & CNS Big Data
Pioneering Therapeutics for Fibrosis
Theraly Fibrosis is a preclinical-stage company whose mission is to develop innovative treatments for various forms of fibrotic disease including chronic pancreatitis, systemic sclerosis, and NASH. The company’s lead candidate, TLY012, selectively targets myofibroblasts, cells believed to be the critical originators of fibrosis, a condition that affects a variety of tissues.
Contact Us
Want to learn more about Theraly Fibrosis or have a question about our approach? Use the contact form and let’s start a conversation.